215
Participants
Start Date
July 18, 2019
Primary Completion Date
November 1, 2023
Study Completion Date
December 1, 2023
Methotrexate
Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
Placebo
Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
Peking Union Medical College University, Beijing
Peking University People's Hospital, Beijing
Xuanwu Hospital Capital Medical University, Beijing
The 1st Affiliated Hospital of Anhui Medical University, Hefei
Zhujiang Hospital, Guangzhou
Beijing Hospital, Beijing
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou
Second People's Hospital of Guangdong Province, Guanzhou
Qingyuan People's Hospital, Qingyuan
The Third Hospital of Shenzhen, Shenzhen
Central People's Hospital of Zhanjiang, Zhanjiang
Peking Union Medical College Hospital
OTHER
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Beijing Hospital
OTHER_GOV
Xuanwu Hospital, Beijing
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
The Second People's Hospital of GuangDong Province
OTHER
Peking University People's Hospital
OTHER
Shenzhen Third People's Hospital
OTHER
Central People's Hospital of Zhanjiang
OTHER
Qingyuan People's Hospital
OTHER
Zhujiang Hospital
OTHER